FTY720 controls disease severity and attenuates sciatic nerve damage in chronic experimental autoimmune neuritis

• Published in: Journal of neuroinflammation 2019-03, Vol.16 (1), p.54-54, Article 54
• Main Authors: Kremer, Laurent, Taleb, Omar, Boehm, Nelly, Mensah-Nyagan, Ayikoe Guy, Trifilieff, Elisabeth, de Seze, Jérôme, Brun, Susana
• Format: Article
• Language: English
• Subjects: Animal models; Autoimmune diseases; Autophagy; c-EAN; Chronic illnesses; Chronic inflammatory demyelinating polyradiculoneuropathy; Clinical trials; Cytokines; Demyelination; Drug therapy; Enzyme-linked immunosorbent assay; Experimental allergic neuritis; Fibers; Fingolimod; Flow cytometry; FTY720; Guillain-Barre syndrome; Immunization; Immunomodulation; Inflammatory diseases; Inflammatory neuropathies; Interleukin 17; Life Sciences; Lymph nodes; Lymphocytes; Macrophages; Medical examination; Mimicry; Multiple sclerosis; Myelin; Myelin P0 protein; Nervous system; Neuritis; Neurobiology; Neurodegeneration; Neurons and Cognition; Patient outcomes; Peptides; Peripheral blood; Peripheral nerves; Peripheral neuropathy; Sciatic nerve; Serum levels; Sphingosine 1-phosphate
• ISSN: 1742-2094; 1742-2094
• DOI: 10.1186/s12974-019-1441-4

Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is an autoimmune-mediated inflammatory disease of the peripheral nervous system characterized by a response directed against certain myelin proteins and for which therapies are limited. Previous studies have suggested a beneficial role of FTY720, a sphingosine 1-phosphate (S1P) receptor agonist, known to deplete lymphocytes from the peripheral blood by sequestering them into lymph nodes, in the treatment of experimental autoimmune neuritis (EAN). Therefore, we investigated whether FTY720 is also beneficial in chronic experimental autoimmune neuritis (c-EAN), a recently developed rat model mimicking human CIDP. c-EAN was induced in Lewis rats by immunization with S-palm P0(180-199) peptide. Rats were treated with FTY720 (1 mg/kg) or vehicle intraperitoneally once daily from the onset of clinical signs for 18 days; clinical signs were assessed daily until 60 days post-immunization (dpi). Electrophysiological and histological features were examined at different time points. We also evaluated the serum levels of different pro- and anti-inflammatory cytokines by ELISA or flow cytometry at 18, 40, and 60 dpi. Our data demonstrate that FTY720 decreased the severity and abolished the chronicity of the disease in c-EAN rats. Therapeutic FTY720 treatment reversed electrophysiological and histological anomalies, suggesting that myelinated fibers were subsequently preserved, it inhibited macrophage and IL-17 cell infiltration in PNS, and it significantly reduced circulating pro-inflammatory cytokines. FTY720 treatment has beneficial effects on c-EAN, a new animal model mimicking human CIDP. We have shown that FTY720 is an effective immunomodulatory agent, improving the disease course of c-EAN, preserving the myelinated fibers, attenuating the axonal degeneration, and decreasing the number of infiltrated inflammatory cells in peripheral nerves. These data confirm the interest of testing FTY720 or molecules targeting S1P in human peripheral neuropathies.